GSK plc's filing presents significant overall survival data from the DREAMM-7 trial, showing a 42% reduction in death risk for multiple myeloma, with a median overall survival of 84 months for Blenrep combination therapy compared to 51 months for the standard treatment, daratumumab, based on a follow-up date of December 9, 2024.